Company Profile
Intra-Cellular Therapies Stock Price, News & Analysis
Company overview
Business overview
Intra-Cellular Therapies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Intra-Cellular Therapies is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Intra-Cellular Therapies follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Intra-Cellular Therapies sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ITCI is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Intra-Cellular Therapies’ catalysts are Caplyta growth, label-expansion work, and any CNS pipeline update that broadens the franchise. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.